Edition: BP 2025 (Ph. Eur. 11.6 update).<\/p>\n
Action and use<\/strong><\/p>\n Alpha1-adrenoceptor antagonist.<\/p>\n Alfuzosin Tablets contain Alfuzosin Hydrochloride.<\/p>\n The tablets comply with the requirements stated under Tablets and with the following requirements.<\/p>\n Content of alfuzosin hydrochloride, C19<\/sub>H27<\/sub>N5<\/sub>O4<\/sub>,HCl<\/strong><\/p>\n 95.0 to 105.0% of the stated amount.<\/p>\n Shake a quantity of the powdered tablets containing 30 mg of Alfuzosin Hydrochloride with 50 mL of water for 5 minutes and filter. Adjust the pH of the filtrate to 12.5 with 18M ammonia extract with two 25-mL quantities of dichloromethane, wash the combined extracts with 10 mL of water, dry over sodium sulfate and evaporate to dryness. The infrared absorption spectrum, Appendix II A, is concordant with the reference spectrum of alfuzosin ( RS 446).<\/p>\n Comply with the dissolution test for tablets and capsules, Appendix XII B1.<\/p>\n (a) Use Apparatus 2, rotating the paddle at 50 revolutions per minute.<\/p>\n (b) Use 900 mL of water, at a temperature of 37\u00b0, as the medium.<\/p>\n Carry out the method for liquid chromatography, Appendix III D, using the following solutions in the mobile phase.<\/p>\n (1) After 45 minutes withdraw a sample of the medium and filter. Use the filtered medium, diluted with mobile phase if necessary, to produce a solution expected to contain 0.0001% w\/v of Alfuzosin Hydrochloride.<\/p>\n (2) 0.0001% w\/v of alfuzosin hydrochloride BPCRS.<\/p>\n (3) 0.01% w\/v of alfuzosin impurity standard BPCRS.<\/p>\n The chromatographic conditions described under Related substances may be used. Inject 100 \u00b5L of each solution.<\/p>\n The test is not valid unless:<\/p>\n the chromatogram obtained with solution (3) closely resembles the reference chromatogram supplied with alfuzosin impurity standard BPCRS;<\/p>\n the resolution between the peaks due to impurity D and impurity E is at least 2.0; the resolution between the peaks due to alfuzosin and impurity A is at least 2.0.<\/p>\n Calculate the total content of alfuzosin hydrochloride, C19H27N5O4,HCl, in the medium from the chromatograms obtained and using the declared content of C19H27N5O4,HCl in alfuzosin hydrochloride BPCRS.<\/p>\n The amount of alfuzosin hydrochloride released is not less than 75% (Q) of the stated amount.<\/p>\n Carry out the method for liquid chromatography, Appendix III D, using the following solutions.<\/p>\n (1) Shake a quantity of powdered tablets containing 15 mg of Alfuzosin Hydrochloride in 70 mL of methanol for 30 minutes, add 10 mL of 0.01M hydrochloric acid, cool, dilute to 100 mL with methanol and filter. Dilute 1 volume of the solution to 5 volumes with the mobile phase.<\/p>\n (2) Dilute 1 volume of solution (1) to 200 volumes with the mobile phase.<\/p>\n (3) Dilute 2 volumes of solution (2) to 5 volumes with the mobile phase.<\/p>\n (4) Dilute 1 volume of solution (2) to 5 volumes with the mobile phase.<\/p>\n (5) 0.01% w\/v of alfuzosin impurity standard BPCRS in the mobile phase.<\/p>\n (a) Use a stainless steel column (15 cm \u00d7 4.6 mm) packed with end-capped octadecylsilyl silica gel for chromatography (5 \u00b5m) (Inertsil ODS2 is suitable).<\/p>\n (b) Use isocratic elution and the mobile phase described below.<\/p>\n (c) Use a flow rate of 1.5 mL per minute.<\/p>\n (d) Use an ambient column temperature.<\/p>\n (e) Use a detection wavelength of 254 nm.<\/p>\n (f) Inject 20 \u00b5L of each solution.<\/p>\n (g) For solution (1), allow the chromatography to proceed for twice the retention time of the principal peak.<\/p>\n 1 volume of tetrahydrofuran, 20 volumes of acetonitrile and 80 volumes of sodium perchlorate solution prepared in the following manner. Add 5 mL of perchloric acid to 900 mL of water, adjust to pH 3.5 with 2M sodium hydroxide and add sufficient water to produce 1000 mL.<\/p>\n The test is not valid unless:<\/p>\n the chromatogram obtained with solution (5) closely resembles the reference chromatogram supplied with alfuzosin impurity standard BPCRS;<\/p>\n the resolution between the peaks due to impurity D and impurity E is at least 2.0; the resolution between the peaks due to alfuzosin and impurity A is at least 2.0.<\/p>\n In the chromatogram obtained with solution (1):<\/p>\n the area of any peak corresponding to impurity D (the first eluting peak in the chromatogram obtained with solution (5)) is not greater than the area of the principal peak in the chromatogram obtained with solution (2) (0.5%);<\/p>\n the area of any peak corresponding to impurity E (the second eluting peak in the chromatogram obtained with solution (5)) is not greater than the area of the principal peak in the chromatogram obtained with solution (2) (0.5%);<\/p>\n the area of any other secondary peak is not greater than the area of the principal peak in the chromatogram obtained with solution (3) (0.2%); Disregard any peak with an area less than the area of the principal peak in the chromatogram obtained with solution (4) (0.1%).<\/p>\n Carry out the method for liquid chromatography, Appendix III D, using the following solutions.<\/p>\n (1) Weigh and powder 20 tablets. Shake a quantity of powdered tablets containing 10 mg of Alfuzosin Hydrochloride in 70 mL of methanol for 30 minutes, add 10 mL of 0.01M hydrochloric acid, cool, dilute to 100 mL with methanol and filter. Dilute 1 volume of the resulting solution to 10 volumes with the mobile phase.<\/p>\n (2) 0.001% w\/v of alfuzosin hydrochloride BPCRS in the mobile phase.<\/p>\n (3) 0.01% w\/v of alfuzosin impurity standard BPCRS in the mobile phase.<\/p>\n The chromatographic conditions described under Related substances may be used.<\/p>\n The Assay is not valid unless:<\/p>\n the chromatogram obtained with solution (3) closely resembles the reference chromatogram supplied with alfuzosin impurity standard BPCRS;<\/p>\n the resolution between the peaks due to impurity D and impurity E is at least 2.0; the resolution between the peaks due to alfuzosin and impurity A is at least 2.0.<\/p>\n Calculate the content of C19H27N5O4,HCl in the tablets from the chromatograms obtained and using the declared content of C19H27N5O4,HCl in alfuzosin hydrochloride BPCRS.<\/p>\n The impurities limited by the requirements of this monograph include those listed under Alfuzosin Hydrochloride.<\/p>\n","protected":false},"excerpt":{"rendered":" Edition: BP 2025 (Ph. Eur. 11.6 update). Action and use Alpha1-adrenoceptor antagonist. DEFINITION Alfuzosin Tablets contain Alfuzosin Hydrochloride. The tablets comply with the requirements stated under Tablets and with the following requirements. Content of alfuzosin hydrochloride, C19H27N5O4,HCl 95.0 to 105.0% of the stated amount. IDENTIFICATION Shake a quantity of the powdered tablets containing 30 mg…<\/p>\n","protected":false},"author":5,"featured_media":2948,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[175],"tags":[],"class_list":["post-2942","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-formulated-preparations-specific-monographs"],"acf":[],"_links":{"self":[{"href":"https:\/\/nhathuocngocanh.com\/bp\/wp-json\/wp\/v2\/posts\/2942","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/nhathuocngocanh.com\/bp\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/nhathuocngocanh.com\/bp\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/nhathuocngocanh.com\/bp\/wp-json\/wp\/v2\/users\/5"}],"replies":[{"embeddable":true,"href":"https:\/\/nhathuocngocanh.com\/bp\/wp-json\/wp\/v2\/comments?post=2942"}],"version-history":[{"count":5,"href":"https:\/\/nhathuocngocanh.com\/bp\/wp-json\/wp\/v2\/posts\/2942\/revisions"}],"predecessor-version":[{"id":6099,"href":"https:\/\/nhathuocngocanh.com\/bp\/wp-json\/wp\/v2\/posts\/2942\/revisions\/6099"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/nhathuocngocanh.com\/bp\/wp-json\/wp\/v2\/media\/2948"}],"wp:attachment":[{"href":"https:\/\/nhathuocngocanh.com\/bp\/wp-json\/wp\/v2\/media?parent=2942"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/nhathuocngocanh.com\/bp\/wp-json\/wp\/v2\/categories?post=2942"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/nhathuocngocanh.com\/bp\/wp-json\/wp\/v2\/tags?post=2942"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}DEFINITION<\/h2>\n
IDENTIFICATION<\/h2>\n
TESTS<\/h2>\n
Dissolution<\/h3>\n
TEST CONDITIONS<\/h4>\n
PROCEDURE<\/h4>\n
CHROMATOGRAPHIC CONDITIONS<\/h4>\n
SYSTEM SUITABILITY<\/h4>\n
DETERMINATION OF CONTENT<\/h4>\n
LIMITS<\/h4>\n
Related substances<\/h3>\n
CHROMATOGRAPHIC CONDITIONS<\/h4>\n
MOBILE PHASE<\/h4>\n
SYSTEM SUITABILITY<\/h4>\n
LIMITS<\/h4>\n
\nthe sum of the areas of any other secondary peaks is not greater than twice the area of the principal peak in the chromatogram obtained with solution (2) (1.0%).<\/p>\nASSAY<\/h2>\n
CHROMATOGRAPHIC CONDITIONS<\/h3>\n
SYSTEM SUITABILITY<\/h3>\n
DETERMINATION OF CONTENT<\/h3>\n
IMPURITIES<\/h2>\n